相关实验视频

Updated: Jun 12, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

肺腺癌中SMARCA4突变和表达:预后意义和对免疫治疗反应的影响

Yuming Zhang¹, Dantong Sun², Weizhong Han³

¹Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, China.

|September 25, 2024

概括

SMARCA4突变和低表达与肺腺癌 (LUAD) 的较差结果有关. 对于具有SMARCA4突变的LUAD患者,免疫疗法的有效性因同时发生的基因突变而异.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫治疗是一种免疫疗法.

背景情况:

开关/非发酵糖 (SWI/SNF) 复合体在染色质重塑中至关重要,在肺腺癌 (LUAD) 中经常发生变化.
作为SWI/SNF家族成员的SMARCA4在LUAD预后和对免疫治疗的反应中的特定作用尚不清楚.

研究的目的:

研究SMARCA4突变与LUAD患者的临床特征,预后和免疫治疗敏感性之间的关联.
探索SMARCA4改变对瘤突变负担,微卫星不稳定性和瘤免疫微环境的影响.

主要方法:

从cBioPortal数据库中分析6745个LUAD样本,以将SMARCA4突变与预后和临床特征相关联.
检查两个与免疫相关的数据集,以评估SMARCA4突变与免疫治疗反应之间的关系.
评估共突变模式及其对治疗结果的影响.

主要成果:

在LUAD中,SMARCA4突变和低表达与更短的生存期和增加的瘤突变负担和微卫星不稳定性有关.
SMARCA4突变经常与KRAS,KEAP1,TP53和STK11突变同时发生.
根据单独的SMARCA4突变状态,没有发现免疫治疗反应的显著差异,但KRAS/STK11共同突变的疗效较差,SMARCA4/TP53共同突变的疗效有所改善.
低SMARCA4表达与更高的免疫度和改变的免疫微环境特征相关.

结论:

SMARCA4突变和减少表达是LUAD预后不佳的潜在指标.
在患有SMARCA4突变的LUAD患者中,免疫治疗的疗效受到共变基因的存在的影响,特别是TP53.
SMARCA4 状态可以作为 LUAD 诊断和治疗策略的有价值的生物标志物.

关键词:

这就是SMARCA4的标志.在 SWI/SNF 复合体中.免疫疗法敏感性免疫疗法敏感性肺部腺癌的癌症.预后预后预后

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...